SEC Filing Analysis: Innoviva, Inc. (INVA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chief Financial Officer received a routine compensatory grant of Restricted Stock Units (RSUs) valued at approximately $500,000.
• Market Impact: This transaction is considered neutral as it is a standard form of executive compensation and not an open-market purchase, representing a very small fraction of the company's market value.

Company Information

Field	Value
Company	Innoviva, Inc.
Ticker Symbol	INVA
CIK	0001080014
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Basso Stephen
CIK	0001815707
Title/Position	Chief Financial Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-03
Transaction Code	A (Grant)
Security Type	Common Stock (as RSUs)
Shares Involved	27,609
Price Per Share	$18.11
Total Value	$499,918.99
Shares Owned After	50,890
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$499,918.99
% of Market Cap	0.043%
Shares Transacted	27,609
% of Shares Outstanding	0.044%
Post-Transaction Ownership	50,890 shares (0.081% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction's value of ~$500k is negligible relative to Innoviva's $1.15 billion market capitalization.
• Ownership Concentration: The grant modestly increases the CFO's holdings, which remain less than 0.1% of total shares outstanding.
• Dilution Impact: The issuance of 27,609 shares represents a minimal dilution of 0.044% to existing shareholders, which is a routine aspect of equity compensation plans.
• Transaction Significance: The transaction is classified as having low significance. Both its value relative to market cap and the share count relative to outstanding shares fall well below the thresholds for moderate or high significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a pre-approved, compensatory grant of RSUs, not an open-market transaction. Such events are standard practice for executive compensation and do not typically influence stock price.

Volume & Sentiment

• Expected Volume Impact: None. The grant does not involve a market trade.
• Sentiment Indicator: Neutral. The filing is informational and does not reflect a bullish or bearish stance from the insider.

Additional Context

Transaction Notes

• Special Circumstances: The filing footnote clarifies this is a grant of time-vested Restricted Stock Units (RSUs). The shares vest over a multi-year period, starting November 20, 2026, contingent on continued service. This confirms the compensatory nature of the transaction.